Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug (casdozo, SRF388) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced, or metastatic hepatocellular carcinoma (uHCC).
Journal
Journal of Clinical Oncology
Series/Report No.
Journal of Clinical Oncology
Journal Volume
42
Start Page
470
End Page
470
Date Issued
2024-01-20
Author(s)
Li, Daneng
Rau, Kun-Ming
Yu, Ming-Lung
Chon, Hong Jae
Lai, Hsueh-Chou
Pelster, Meredith
Roberts, Stuart K.
Crysler, Oxana V.
Vaccaro, Gina M.
Womack, Mark Sanders
Kim, Ju Won
Yang, Jin-Mo
Kim, Hyung-Don
Hill, Jonathan
REICHERT, VIENNA Lynn
Masia, Ricard
Harshman, Lauren C
Kang, Yoon-Koo
Type
review article